Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the optimal patient population in which she has seen have the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma (CTCL).

Advanced CTCL is life threatening and has a median survival of 2 to 5 years, says Ai, adding that the disease is so rare.

Brentuximab vedotin has shown a significant clinical benefit in advanced stage patients. The drug is the most effective in tumor stage disease, widespread disease, and visceral disease. In a randomized study between brentuximab vedotin and physicians' choice of therapy, methotrexate and vorinostat (Zolinza)—current drugs used in CTCL&mdash;the superiority of brentuximab vedotin by stage of the disease is easily discerned. The most benefit was seen in patients with advanced stage disease.

Videos

Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma.

Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced CTCL

Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, speaks to the relevance of mogamulizumab (Poteligeo) in treating Sezary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma (CTCL).

Data presented from the MAVORIC study revealed that mogamuliazumab is an active drug that clears the blood very quickly and is relatively well tolerated in treating patients with CTCL. The drug is especially active in Sezary syndrome, a leukemia form of CTCL in which statistics reflect an overall survival (OS) of 5 years. Though biologic therapy exists, a proportion of patients who progress require chemotherapy, and many of these patients acquire resistance to the chemotherapy.

With the FDA designation, mogamulizumab is now a novel treatment for patients who have progressed after receiving at least one systemic therapy.

Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, speaks to the relevance of mogamulizumab (Poteligeo) in treating Sezary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma

Weiyun Z. Ai, MD, PhD

Articles

Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced CTCL

Dr. Ai on Potential With Mogamulizumab in CTCL